Condensed Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Statement Condensed Statements Of Operations Unaudited [Line Items]
Product sales	$ 2,444,195	$ 2,129,241	$ 7,211,973	$ 6,377,574
Cost of products sold	677,792	625,710	2,233,944	2,142,661
Gross profit	1,766,403	1,503,531	4,978,029	4,234,913
Selling, general and administrative expenses	1,317,433	1,391,521	4,045,465	4,330,847
Research and development expenses	12,698	60,363	177,419	139,176
Total operating expenses	1,330,131	1,451,884	4,222,884	4,470,023
Income (loss) from operations	436,272	51,647	755,145	(235,110)
Other income (expenses)
Other income	0	0	17,543	0
Interest expense	(5,550)	(36,497)	(70,199)	(142,217)
Interest-Amortization of debt issuance	0	0	0	(3,065)
Loss on Earnings from Medical Joint Venture	(212,199)	0	(259,291)	(124,179)
Total other expenses	(217,749)	(36,497)	(311,868)	(269,461)
Net income (loss)	$ 218,523	$ 15,150	$ 443,277	$ (504,571)
Net income (loss) per share applicable to common stockholders –
Basic	$ 0.01	$ 0	$ 0.03	$ 0
Diluted	$ 0.01	$ 0	$ 0.03	$ 0
Weighted average shares outstanding and to be issued –
Basic	17,333,941	16,244,800	16,955,048	15,953,925
Diluted	17,716,964	16,369,814	17,322,388	15,953,925